Exhibit 99.1 Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update Norwood, MA, March 12, 2024 (GLOBE NEWSWIRE) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023. "In 2023 we made significant progress in advancing our pipeline to meaningful mile ...

Personalized health screening from a “smart toilet” … how AI will revolutionize healthcare … transformative wellness care and bottom-line cost savings … how our experts are playing itIt’s a day not too far off in the future…You wake, enjoy a cup of coffee, then make a trip to the bathroom. Only this is no regular bathroom…Your home now has a “smart toilet.” Powered by artificial intelligence, it analyzes your deposit in real time, scanning for the first sign of any illness or disease.Here’s Sanjay Mehrotra, ...

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partners ...

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Presentation and one-on-one investor meetingsPr ...

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Presentation and one-on-one investor meetingsP ...

Key PointsCorbus Pharmaceuticals has surged over 300% year-to-date after releasing promising data on January 26 from its Phase 1 trial on CRB-701.Oppenheimer's target raise to $51, alongside a significant insider purchase, signals optimism for Corbus Pharmaceuticals.Recent insider purchasing of over $9 million indicates strong confidence in Corbus Pharmaceuticals' future.5 stocks we like better than Corbus PharmaceuticalsShares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise ...

NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the common stock was sold at a public offering price of $19.00 per share for a total public offering ...

NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to ...

Andy Roberts/OJO Images via Getty Images Topline Summary Corbus Pharmaceuticals (NASDAQ:CRBP) is a microcap biotech company focused on the development of novel therapies for the treatment of cancer. They've recently experienced a meteoric surge out of the depths on the back of a positive clinical readout, but it remains very early days for the company's overall pipeline, and cash is not sufficient to keep the ball rolling without some significant financing needed. It's best to hold off on this one for n ...

The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29. CRBP was previously trading at a meagre valuation below $7. Despite the stock trading almost 25% lower in premarket on Monday, the developments are worth attention. Corbus Pharmaceuticals is a precision oncology company seeking to help people defeat serious illnesses. The company targets very rare and serious diseases us ...